## Rémi Longuespée

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/8140076/publications.pdf Version: 2024-02-01



PÃOMILONCUESPÃOE

#	Article	IF	CITATIONS
1	Tyrosine Kinase Inhibitors in Cancer: Breakthrough and Challenges of Targeted Therapy. Cancers, 2020, 12, 731.	3.7	280
2	Automated sample preparation with <scp>SP</scp> 3 for lowâ€input clinical proteomics. Molecular Systems Biology, 2020, 16, e9111.	7.2	133
3	MALDI imaging and profiling MS of higher mass proteins from tissue. Journal of the American Society for Mass Spectrometry, 2010, 21, 1922-1929.	2.8	110
4	Tumor resistance to ferroptosis driven by Stearoyl-CoA Desaturase-1 (SCD1) in cancer cells and Fatty Acid Biding Protein-4 (FABP4) in tumor microenvironment promote tumor recurrence. Redox Biology, 2021, 43, 102006.	9.0	102
5	Siteâ€ŧo‣ite Reproducibility and Spatial Resolution in MALDI–MSI of Peptides from Formalinâ€Fixed Paraffinâ€Embedded Samples. Proteomics - Clinical Applications, 2019, 13, e1800029.	1.6	73
6	A laser microdissection-based workflow for FFPE tissue microproteomics: Important considerations for small sample processing. Methods, 2016, 104, 154-162.	3.8	72
7	Multivariate analyses for biomarkers hunting and validation through on-tissue bottom-up or in-source decay in MALDI-MSI: application to prostate cancer. Analytical and Bioanalytical Chemistry, 2011, 401, 149-165.	3.7	71
8	MALDI mass spectrometry imaging: A cuttingâ€edge tool for fundamental and clinical histopathology. Proteomics - Clinical Applications, 2016, 10, 701-719.	1.6	70
9	MALDI imaging mass spectrometry in ovarian cancer for tracking, identifying, and validating biomarkers. Medical Science Monitor, 2010, 16, BR233-45.	1.1	60
10	The importance of the tumor microenvironment in the therapeutic management of cancer. Expert Review of Anticancer Therapy, 2015, 15, 943-954.	2.4	58
11	Ovarian cancer molecular pathology. Cancer and Metastasis Reviews, 2012, 31, 713-732.	5.9	57
12	MALDI mass spectrometry imaging of proteins exceeding 30,000 daltons. Medical Science Monitor, 2010, 16, BR293-9.	1.1	52
13	Tissue Proteomics for the Next Decade? Towards a Molecular Dimension in Histology. OMICS A Journal of Integrative Biology, 2014, 18, 539-552.	2.0	48
14	OLFM4, KNG1 and Sec24C identified by proteomics and immunohistochemistry as potential markers of early colorectal cancer stages. Clinical Proteomics, 2017, 14, 9.	2.1	45
15	A spiked tissue-based approach for quantification of phosphatidylcholines in brain section by MALDI mass spectrometry imaging. Analytical and Bioanalytical Chemistry, 2015, 407, 2095-2106.	3.7	42
16	Selected Protein Monitoring in Histological Sections by Targeted MALDI-FTICR In-Source Decay Imaging. Analytical Chemistry, 2013, 85, 2117-2126.	6.5	38
17	MALDI Imagingâ€Guided Microproteomic Analyses of Heterogeneous Breast Tumors—A Pilot Study. Proteomics - Clinical Applications, 2018, 12, 1700062	1.6	33
18	Insulinoma-associated Protein 1 (INSM1) in Thoracic Tumors is Less Sensitive but More Specific Compared With Synaptophysin, Chromogranin A, and CD56. Applied Immunohistochemistry and Molecular Morphology, 2020, 28, 237-242.	1.2	33

#	Article	IF	CITATIONS
19	Proteomic signatures reveal a dualistic and clinically relevant classification of anal canal carcinoma. Journal of Pathology, 2017, 241, 522-533.	4.5	32
20	Accelerated preâ€senile systemic amyloidosis in PACAP knockout mice–Âa protective role of PACAP in ageâ€related degenerative processes. Journal of Pathology, 2018, 245, 478-490.	4.5	32
21	Programmed cell death ligand 1 (PD-L1, CD274) in cholangiocarcinoma – correlation with clinicopathological data and comparison of antibodies. BMC Cancer, 2019, 19, 72.	2.6	32
22	Implications of Proprotein Convertases in Ovarian Cancer Cell Proliferation and Tumor Progression: Insights for PACE4 as a Therapeutic Target. Translational Oncology, 2014, 7, 410-419.	3.7	30
23	Microproteomic sample preparation. Proteomics, 2021, 21, e2000318.	2.2	30
24	The C-terminal fragment of the immunoproteasome PA28S (Reg alpha) as an early diagnosis and tumor-relapse biomarker: evidence from mass spectrometry profiling. Histochemistry and Cell Biology, 2012, 138, 141-154.	1.7	29
25	Multi-Enzymatic Limited Digestion: The Next-Generation Sequencing for Proteomics?. Journal of Proteome Research, 2019, 18, 2501-2513.	3.7	29
26	Rapid detection of 2-hydroxyglutarate in frozen sections of IDH mutant tumors by MALDI-TOF mass spectrometry. Acta Neuropathologica Communications, 2018, 6, 21.	5.2	28
27	Role of conventional immunomarkers, <scp>HNF</scp> 4â€Ĵ± and <scp>SATB</scp> 2, in the differential diagnosis of pulmonary and colorectal adenocarcinomas. Histopathology, 2018, 72, 997-1006.	2.9	24
28	Combined Immunohistochemistry after Mass Spectrometry Imaging for Superior Spatial Information. Proteomics - Clinical Applications, 2019, 13, e1800035.	1.6	23
29	Cytomine: Toward an Open and Collaborative Software Platform for Digital Pathology Bridged to Molecular Investigations. Proteomics - Clinical Applications, 2019, 13, e1800057.	1.6	23
30	Targeted liquid chromatographyâ€ŧandem mass spectrometry analysis of proteins: Basic principles, applications, and perspectives. Proteomics, 2021, 21, e2100153.	2.2	23
31	Spatial distribution of <i>EGFR</i> and <i>KRAS</i> mutation frequencies correlates with histological growth patterns of lung adenocarcinomas. International Journal of Cancer, 2017, 141, 1841-1848.	5.1	21
32	Typing of colon and lung adenocarcinoma by high throughput imaging mass spectrometry. Biochimica Et Biophysica Acta - Proteins and Proteomics, 2017, 1865, 858-864.	2.3	20
33	Comparison of two FFPE preparation methods using label-free shotgun proteomics: Application to tissues of diverticulitis patients. Journal of Proteomics, 2015, 112, 250-261.	2.4	19
34	Digital PCR After MALDI–Mass Spectrometry Imaging to Combine Proteomic Mapping and Identification of Activating Mutations in Pulmonary Adenocarcinoma. Proteomics - Clinical Applications, 2019, 13, e1800034.	1.6	19
35	In MALDI–Mass Spectrometry Imaging on Formalinâ€Fixed Paraffinâ€Embedded Tissue Specimen Section Thickness Significantly Influences <i>m/z</i> Peak Intensity. Proteomics - Clinical Applications, 2019, 13, e1800074.	1.6	19
36	Proteomic analyses of serous and endometrioid epithelial ovarian cancers – Cases studies – Molecular insights of a possible histological etiology of serous ovarian cancer. Proteomics - Clinical Applications, 2013, 7, 337-354.	1.6	18

RéMI LONGUESPéE

#	Article	IF	CITATIONS
37	Laser Microdissection-Based Microproteomics of Formalin-Fixed and Paraffin-Embedded (FFPE) Tissues. Methods in Molecular Biology, 2018, 1723, 19-31.	0.9	18
38	Proteomics in Pathology. Proteomics, 2018, 18, 1700361.	2.2	18
39	Proteomic investigation of human cystic echinococcosis in the liver. Molecular and Biochemical Parasitology, 2017, 211, 9-14.	1.1	17
40	PAT-H-MS coupled with laser microdissection to study histone post-translational modifications in selected cell populations from pathology samples. Clinical Epigenetics, 2017, 9, 69.	4.1	17
41	Identification of MALDI Imaging Proteolytic Peptides Using LCâ€MS/MSâ€Based Biomarker Discovery Data: A Proof of Concept. Proteomics - Clinical Applications, 2019, 13, e1800158.	1.6	17
42	Approaching Sites of Action of Temozolomide for Pharmacological and Clinical Studies in Glioblastoma. Biomedicines, 2022, 10, 1.	3.2	17
43	Spectroimmunohistochemistry: A Novel Form of MALDI Mass Spectrometry Imaging Coupled to Immunohistochemistry for Tracking Antibodies. OMICS A Journal of Integrative Biology, 2014, 18, 132-141.	2.0	16
44	Detection of HPV subtypes by mass spectrometry in FFPE tissue specimens: a reliable tool for routine diagnostics. Journal of Clinical Pathology, 2017, 70, 417-423.	2.0	16
45	Subclonal evolution of pulmonary adenocarcinomas delineated by spatially distributed somatic mitochondrial mutations. Lung Cancer, 2018, 126, 80-88.	2.0	16
46	Lipidomics for Clinical Diagnosis: Dye-Assisted Laser Desorption/Ionization (DALDI) Method for Lipids Detection in MALDI Mass Spectrometry Imaging. OMICS A Journal of Integrative Biology, 2014, 18, 487-498.	2.0	15
47	Qualitative Comparison Between Carrier-based and Classical Tissue Microarrays. Applied Immunohistochemistry and Molecular Morphology, 2017, 25, e74-e79.	1.2	15
48	MALDI Imaging for Proteomic Painting of Heterogeneous Tissue Structures. Proteomics - Clinical Applications, 2019, 13, 1800045.	1.6	14
49	Rapid and Sensitive Quantification of Osimertinib in Human Plasma Using a Fully Validated MALDI–IM–MS/MS Assay. Cancers, 2020, 12, 1897.	3.7	14
50	An Improved Molecular Histology Method for Ion Suppression Monitoring and Quantification of Phosphatidyl Cholines During MALDI MSI Lipidomics Analyses. OMICS A Journal of Integrative Biology, 2016, 20, 110-121.	2.0	13
51	Microproteomic Profiling of Highâ€Grade Squamous Intraepithelial Lesion of the Cervix: Insight into Biological Mechanisms of Dysplasia and New Potential Diagnostic Markers. Proteomics - Clinical Applications, 2019, 13, 1800052.	1.6	13
52	Rapid and Sensitive Drug Quantification in Tissue Sections Using Matrix Assisted Laser Desorption Ionization-Ion Mobility-Mass Spectrometry Profiling. Journal of the American Society for Mass Spectrometry, 2020, 31, 742-751.	2.8	13
53	An optimized MALDI MSI protocol for spatial detection of tryptic peptides in fresh frozen prostate tissue. Proteomics, 2022, 22, e2100223.	2.2	13
54	Mass spectrometry in pathology – Vision for a future workflow. Pathology Research and Practice, 2018, 214, 1057-1063.	2.3	12

RéMI LONGUESPéE

#	Article	IF	CITATIONS
55	Automation of singleâ€cell proteomic sample preparation. Proteomics, 2021, 21, e2100198.	2.2	12
56	Rapid drug detection in whole blood droplets using a desorption electrospray ionization static profiling approach – a proofâ€ofâ€concept. Rapid Communications in Mass Spectrometry, 2020, 34, e8614.	1.5	11
57	Rapid MALDI-MS Assays for Drug Quantification in Biological Matrices: Lessons Learned, New Developments, and Future Perspectives. Molecules, 2021, 26, 1281.	3.8	11
58	Human peripheral blood mononuclear cells: A review of recent proteomic applications. Proteomics, 2022, , 2200026.	2.2	11
59	Development and Validation of an LC–MS-Based Quantification Assay for New Therapeutic Antibodies: Application to a Novel Therapy against Herpes Simplex Virus. ACS Omega, 2020, 5, 24329-24339.	3.5	10
60	Periostin in lymph node pre-metastatic niches governs lymphatic endothelial cell functions and metastatic colonization. Cellular and Molecular Life Sciences, 2022, 79, 295.	5.4	10
61	Approaching sites of action of drugs in clinical pharmacology: New analytical options and their challenges. British Journal of Clinical Pharmacology, 2021, 87, 858-874.	2.4	9
62	Expression of HMB45, MelanA and SOX10 is rare in non-small cell lung cancer. Diagnostic Pathology, 2018, 13, 68.	2.0	8
63	Proteomics in Pathology: The Special Issue. Proteomics - Clinical Applications, 2019, 13, e1800167.	1.6	8
64	Desorption/Ionization-MS Methods for Drug Quantification in Biological Matrices and Their Validation Following Regulatory Guidance. Analytical Chemistry, 2021, 93, 7152-7163.	6.5	8
65	Matrixâ€assisted laser desorption/ionization mass spectrometry and Raman spectroscopy: An interesting complementary approach for lipid detection in biological tissues. European Journal of Lipid Science and Technology, 2014, 116, 1080-1086.	1.5	7
66	HFIP Extraction Followed by 2D CTAB/SDS-PAGE Separation: A New Methodology for Protein Identification from Tissue Sections after MALDI Mass Spectrometry Profiling for Personalized Medicine Research. OMICS A Journal of Integrative Biology, 2014, 18, 374-384.	2.0	7
67	Microproteomics and Immunohistochemistry Reveal Differences in Aldoâ€Keto Reductase Family 1 Member C3 in Tissue Specimens of Ulcerative Colitis and Crohn's Disease. Proteomics - Clinical Applications, 2020, 14, e1900110.	1.6	7
68	Automated Morphological and Morphometric Analysis of Mass Spectrometry Imaging Data: Application to Biomarker Discovery. Journal of the American Society for Mass Spectrometry, 2017, 28, 2635-2645.	2.8	6
69	Conventional and semi-automatic histopathological analysis of tumor cell content for multigene sequencing of lung adenocarcinoma. Translational Lung Cancer Research, 2021, 10, 1666-1678.	2.8	6
70	Analytical Performance Evaluation of New DESI Enhancements for Targeted Drug Quantification in Tissue Sections. Pharmaceuticals, 2022, 15, 694.	3.8	6
71	MALDI Imaging Combined with Laser Microdissection-Based Microproteomics for Protein Identification: Application to Intratumor Heterogeneity Studies. Methods in Molecular Biology, 2017, 1788, 297-312.	0.9	5
72	Analysis of the proliferative activity in lung adenocarcinomas with specific driver mutations. Pathology Research and Practice, 2018, 214, 408-416.	2.3	4

## Rémi Longuespée

#	Article	IF	CITATIONS
73	Advances in Clinical Pharmacology: Rapid Detection of Small Molecules in Solid Samples at Atmospheric Pressure Using Desorption Electrospray Ionization. OMICS A Journal of Integrative Biology, 2020, 24, 53-54.	2.0	4
74	Important Requirements for the Selection of Internal Standards during the Development of Desorption/Ionization Assays for Drug Quantification in Biological Matrices—A Practical Example. Molecules, 2022, 27, 690.	3.8	2
75	Back Cover: MALDI Imaging-Guided Microproteomic Analyses of Heterogeneous Breast Tumors-A Pilot Study. Proteomics - Clinical Applications, 2018, 12, 1870005.	1.6	1
76	Front cover: MALDI mass spectrometry imaging: A cutting-edge tool for fundamental and clinical histopathology. Proteomics - Clinical Applications, 2016, 10, NA-NA.	1.6	0
77	Inside Front Cover: Microproteomic Profiling of Highâ€Grade Squamous Intraepithelial Lesion of the Cervix: Insight into Biological Mechanisms of Dysplasia and New Potential Diagnostic Markers. Proteomics - Clinical Applications, 2019, 13, 1970012.	1.6	0
78	Abstract LB-187: MALDI imaging-guided microproteomics workflow for intratumor heterogeneity studies. , 2016, , .		0
79	Site-to-site reproducibility of matrix-assisted laser desorption ionization mass spectrometry imaging from formalin-fixed paraffin-embedded samples. Pathology, 2019, 51, S91.	0.6	0
80	LGG-25. The first-in-class ERK inhibitor ulixertinib (BVD-523) shows activity in MAPK-driven pediatric low-grade glioma models as single agent and in combination with MEK inhibitors or senolytics. Neuro-Oncology, 2022, 24, i93-i93.	1.2	0